Lilly approves $15 billion share buyback and raises its dividend 15%
Lilly is returning more cash to shareholders while saying its spending priorities stay on launches, manufacturing and research, a mix that does not by itself change what patients pay or how their medicines are covered.
Eli Lilly's board of directors approved a new $15 billion share repurchase program and a 15% increase in the company's quarterly dividend, Lilly announced on Dec. 9, 2024 [1]. The dividend increase is the seventh consecutive year at that rate, and the board declared a first-quarter 2025 dividend of $1.50 per share [1].
The new buyback replaces a prior $5 billion share repurchase program that the company said was completed in the fourth quarter of 2024 [1]. Lilly said it expects to execute the new program over the next three years, but the program itself has no time limit and may be suspended or discontinued at any time [1].
The dividend is payable on March 10, 2025, to shareholders of record at the close of business on Feb. 14, 2025 [1].
Lilly executive vice president and chief financial officer Lucas Montarce said the company's capital allocation priorities are unchanged. "As Lilly has entered into a period of rapid growth, our capital allocation priorities remain the same. We will continue to focus on supporting new launches, expanding our manufacturing capacity, and advancing our pipeline through research and development and business development," he said. "However, given the strong growth profile of the company, we're also increasing the amount of capital we plan to return to shareholders. We expect to execute this program over the next three years" [1].
Buybacks may be made from time to time at management's discretion, the company said, using open market purchases, accelerated share repurchases or other privately negotiated transactions [1].
The announcement does not name any specific medicine or say which products are generating the cash behind the buyback and dividend [1]. Lilly describes its business broadly, listing diabetes care, treating obesity, Alzheimer's disease, immune system disorders and cancer among its areas of work [1]. No link between this capital-return decision and Mounjaro or Zepbound, the company's tirzepatide medicines, was disclosed in the announcement [1].
Why it matters for patients
A share buyback and a dividend increase are ways to return cash to shareholders. They do not by themselves change what a medicine costs, whether an insurer covers it, or how it is prescribed, and this announcement includes no changes to pricing, coverage or patient assistance programs [1].
The one patient-relevant area Lilly names in the release is company spending: supporting new product launches, expanding manufacturing capacity and advancing its research pipeline [1]. The release does not say how much money goes to each of those priorities, or whether those budgets change as a result of the buyback [1].
The release also does not address supply levels, access programs or list prices for any Lilly product, and no figures on those topics were included [1].
What happens next
Shareholders of record as of Feb. 14, 2025 will receive the $1.50 quarterly dividend on March 10, 2025 [1]. The buyback has no fixed schedule: Lilly says it expects to execute the program over three years, but it can pause or end the purchases at any time, and management decides when and how many shares to buy [1]. No other dates or spending targets were given [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.